Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-018-2258-1
Abstract: CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We investigated the role of soluble CTLA-4 (sCTLA-4) as a possible… read more here.
Keywords: melanoma; ipi; ctla; sctla ... See more keywords
Structure Based Screening for Inhibitory Therapeutics of CTLA-4 Unveiled New Insights About Biology of ACTH
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Peptide Research and Therapeutics"
DOI: 10.1007/s10989-019-09891-7
Abstract: Although the biology of adrenocorticotropic hormone (ACTH) protein has already been scrutinized, some functional aspects of its biology are yet to be elucidated in the context of immunological disorders. In this regard, virtual screening of… read more here.
Keywords: ctla; structure based; biology; acth ... See more keywords
Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop
Sign Up to like & getrecommendations! Published in 2021 at "Cell"
DOI: 10.1016/j.cell.2021.05.027
Abstract: Foxp3+ T regulatory (Treg) cells promote immunological tumor tolerance, but how their immune-suppressive function is regulated in the tumor microenvironment (TME) remains unknown. Here, we used intravital microscopy to characterize the cellular interactions that provide… read more here.
Keywords: treg cells; tumor associated; ctla; treg cell ... See more keywords
CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes.
Sign Up to like & getrecommendations! Published in 2017 at "Gene"
DOI: 10.1016/j.gene.2017.09.010
Abstract: T cell-mediated anti-tumor immunity plays a pivotal role in cancer immune surveillance. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a protein receptor mainly expressed in activated T cells and regulatory T cells. CTLA-4 competes with CD28… read more here.
Keywords: tumor activity; cytotoxic; ctla; anti tumor ... See more keywords
Polymorphisms in CTLA-4 predict de novo donor specific antibody formation after kidney transplantation.
Sign Up to like & getrecommendations! Published in 2022 at "Human immunology"
DOI: 10.1016/j.humimm.2022.03.008
Abstract: The post-transplant development of donor-specific antibodies (DSAs) initiates the antibody-mediated rejection, which is associated with an increased rate of graft loss. Therefore, risk prediction of de novo DSA (dnDSA) is important for understanding long-term prognostic… read more here.
Keywords: donor specific; kidney transplantation; dndsa formation; ctla ... See more keywords
HIV-specific CD4+Th17 cells from HIV infected long-term non-progressors exhibit lower CTLA-4 expression and reduced apoptosis.
Sign Up to like & getrecommendations! Published in 2018 at "Immunobiology"
DOI: 10.1016/j.imbio.2018.07.011
Abstract: Progressive HIV infection is marked with reduced frequency and impaired function of Th17 cells. Since T-cell functional responses are regulated by various inhibitory receptors; we examined the expression profile of CTLA-4, PD-1, Tim-3 and apoptotic… read more here.
Keywords: ctla; th17 cells; expression; hiv specific ... See more keywords
Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of dermatological science"
DOI: 10.1016/j.jdermsci.2017.06.013
Abstract: BACKGROUND The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic… read more here.
Keywords: tumor; response; ctla; transcutaneous immunization ... See more keywords
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2018.01.033
Abstract: BACKGROUND & AIMS Immunotherapy for metastatic cancer can be complicated by the onset of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs associated with anti-programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1)… read more here.
Keywords: liver injury; hepatitis; ctla; cancer ... See more keywords
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Cancer"
DOI: 10.1038/bjc.2016.429
Abstract: Background:Although there are reports that metronomic cyclophosphamide (CTX) can be immune stimulating, the impact of its combination with anti-CTLA-4 immunotherapy for the treatment of cancer remains to be evaluated.Methods:Murine EMT-6/P breast cancer, or its cisplatin… read more here.
Keywords: anti ctla; ctla; ctx; breast cancer ... See more keywords
CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation
Sign Up to like & getrecommendations! Published in 2017 at "Cell Death and Differentiation"
DOI: 10.1038/cdd.2017.102
Abstract: The blockade of inhibitory receptors such as CTLA-4 (CD152) is being used as immune-checkpoint therapy, offering a powerful strategy to restore effective immune responses against tumors. To determine signal components that are induced under the… read more here.
Keywords: mediated posttranslational; ctla; ctla mediated; posttranslational modifications ... See more keywords
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Cell Research"
DOI: 10.1038/s41422-019-0184-1
Abstract: It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called checkpoint inhibitors, have severe immunotherapy-related adverse effects (irAEs) and yet suboptimal cancer immunotherapeutic effects (CITE). Here we report that while irAE-prone Ipilimumab and TremeIgG1… read more here.
Keywords: anti ctla; ctla antibodies; ctla; cancer ... See more keywords